Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Quantitative myocardial blood flow with Rubidium-82 PET: a clinical perspective

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Repeatability of FDG PET/CT metrics assessed in free breathing and deep inspiration breath hold in lung cancer patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The value of FDG PET/CT for follow-up of patients with melanoma: a retrospective analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prediction of positron emission tomography/computed tomography (PET/CT) positivity in patients with high-risk primary melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. (18)F-FDG PET imaging in detection of radiation-induced vascular disease in lymphoma survivors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Positron emission tomography (PET) allows assessment of myocardial blood flow in absolute terms (ml/min/g). Quantification of myocardial blood flow (MBF) and myocardial flow reserve (MFR) extend the scope of conventional semi-quantitative myocardial perfusion imaging (MPI): e.g. in 1) identification of the extent of a multivessel coronary artery disease (CAD) burden, 2) patients with balanced 3-vessel CAD, 3) patients with subclinical CAD, and 4) patients with regional flow variance, despite of a high global MFR. A more accurate assessment of the ischemic burden in patients with intermediate pretest probability of CAD can support the clinical decision-making in treatment of CAD patients as a complementary tool to the invasive coronary angiography (CAG). Recently, several studies have proven Rubidium-82 ((82)Rb) PET's long-term prognostic value by a significant association between compromised global MFR and major adverse cardiovascular events (MACE), and together with new diagnostic possibilities from measuring the longitudinal myocardial perfusion gradient, cardiac (82)Rb PET faces a promising clinical future. This article reviews current evidence on quantitative (82)Rb PET's ability to diagnose and risk stratify CAD patients, while assessing the potential of the modality in clinical practice.

OriginalsprogEngelsk
TidsskriftAmerican Journal of Nuclear Medicine and Molecular Imaging
Vol/bind5
Udgave nummer5
Sider (fra-til)457-68
Antal sider12
ISSN2160-8407
StatusUdgivet - 2015

ID: 46267400